: Novo Nordisk’s Wegovy cuts risk of heart attack and stroke by 20% among people without diabetes, study finds

Closely watched clinical trial could help boost insurance coverage of GLP-1 drugs, analysts say.

Previous post : The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman — and Martin Shkreli 
Next post Market Extra: Wall Street hasn’t been this jumpy about a recession since the Volcker era